# Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL

> **NCT05269914** · NA · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 10 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **OTHER:** Autologous anti-CD19 CAR-T cell injection

## Key facts

- **NCT ID:** NCT05269914
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05269914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05269914, "Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05269914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*